DOD Biotech PCL (BKK:DOD) Forward PE Ratio: 0.00 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:DOD DOD Biotech PCL BKK:DOD
65 GF Score
Price ฿0.99
GF Value ฿1.67
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is DOD Biotech PCL Forward PE Ratio?

DOD Biotech PCL BKK:DOD -1.00% 65 Forward PE Ratio is 0.00 as of Aug. 17, 2026. GuruFocus rates BKK:DOD with a GF Score™ of 65/100 and a GF Value™ of ฿1.67 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 747 Consumer Packaged Goods companies, DOD Biotech PCL ranks worse than 133868.67% on this metric.

DOD Biotech PCL's Forward PE Ratio for today is 0.00.

DOD Biotech PCL's PE Ratio without NRI for today is 26.05.

DOD Biotech PCL's PE Ratio (TTM) for today is 49.50.


DOD Biotech PCL  (BKK:DOD) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


DOD Biotech PCL Forward PE Ratio Related Terms


DOD Biotech PCL Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for DOD Biotech PCL's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DOD Biotech PCL Forward PE Ratio Chart

DOD Biotech PCL Annual Data
Trend
Forward PE Ratio

DOD Biotech PCL Quarterly Data
Forward PE Ratio

BKK:DOD vs KHC, GIS: Forward PE Ratio Comparison

For the Packaged Foods subindustry, DOD Biotech PCL's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DOD Biotech PCL Forward PE Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's Forward PE Ratio falls into.


BKK:DOD
65GF Score
DOD Biotech PCL BKK:DOD
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DOD Biotech PCL Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
DOD Biotech PCL (BKK:DOD) has a Forward PE Ratio of 0.00 as of Aug. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on DOD Biotech PCL and its competitors. According to the industry distribution chart, DOD Biotech PCL ranks #999999 out of 747 companies in the Consumer Packaged Goods industry.
Is DOD Biotech PCL's Forward PE Ratio too high?
DOD Biotech PCL's current Forward PE Ratio is 0.00. Based on the distribution chart, DOD Biotech PCL ranks #999999 out of 747 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, DOD Biotech PCL has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's Forward PE Ratio compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, DOD Biotech PCL ranks #999999 out of 747 companies for Forward PE Ratio. This places DOD Biotech PCL in the lower half of its industry. The industry median Forward PE Ratio is 14.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Consumer Packaged Goods company?
The median Forward PE Ratio among Consumer Packaged Goods companies is 14.81, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on DOD Biotech PCL and its competitors. For the Consumer Packaged Goods industry, the median Forward PE Ratio is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DOD Biotech PCL's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
Based on GuruFocus' analysis, DOD Biotech PCL (BKK:DOD) is currently considered Possible Value Trap. The stock's GF Value™ is ฿1.67, compared to a current price of ฿0.99 — trading 40.7% below its estimated fair value. The current Forward PE Ratio is 0.00. DOD Biotech PCL's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD), the current Forward PE Ratio is 0.00 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DOD Biotech PCL (BKK:DOD) Overvalued in 2026?

Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued. The current stock price of ฿0.99 is trading 40.7% below its estimated GF Value™ of ฿1.67. GuruFocus considers DOD Biotech PCL to be Possible Value Trap.

Key valuation signals for BKK:DOD:

  • Forward PE Ratio: 0.00
  • GF Value™: ฿1.67 vs. price of ฿0.99 (40.7% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the BKK:DOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DOD Biotech PCL Business Description

Address No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
65GF Score

Get the complete analysis for BKK:DOD

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿0.99
Price
฿1.67
GF Value